These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14492395)

  • 21. [Causes of Angina Pectoris in Survivors of Myocardial Infarction and the Role of Optimization of Antianginal Therapy. Data of the LINKOR Study E..].
    Glezer MG; Astashkin On Behalf Of The Linkor Study Investigators EI
    Kardiologiia; 2016 Dec; 56(11):5-11. PubMed ID: 28290813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Guidelines and methods for clinical investigation of drugs for treatment of stable angina pectoris].
    Wink K
    Arzneimittelforschung; 2003; 53(12):864-8. PubMed ID: 14732968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinical trial of prenylamine lactate--a long-lasting coronary dilator drug.
    KERRIDGE DF; MAZURKIE SJ; VEREL D
    Can Med Assoc J; 1961 Dec; 85(25):1352-3. PubMed ID: 14455345
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypertensive angina treated with cyclospasmol; report on a case.
    BARRETT CT
    S Afr Med J; 1952 Sep; 26(36):734. PubMed ID: 13005025
    [No Abstract]   [Full Text] [Related]  

  • 25. [Acute exacerbation of coronary artery disease: unstable angina pectoris and myocardial infarction without ST elevations--assessment of risk and proper therapy ].
    Duodecim; 2003; 119(5):430-41. PubMed ID: 12708245
    [No Abstract]   [Full Text] [Related]  

  • 26. The clinical effects of a new anti-anginal agent, prenylamine ("Segontin").
    BAUMGARTEN A
    Med J Aust; 1962 Mar; 49(1)():429-31. PubMed ID: 13865947
    [No Abstract]   [Full Text] [Related]  

  • 27. [New approaches to pharmacodynamic research on anti-angina agents].
    Metelitsa VI; Martsevich SIu; Slastnikova ID; Kokurina EV; Riabokon' OS
    Farmakol Toksikol; 1986; 49(5):56-9. PubMed ID: 3533620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of angina pectoris.
    Brest AN
    Prim Care; 1985 Mar; 12(1):91-100. PubMed ID: 3158019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A clinico-pharmacological study of the antianginal and anti-ischemic efficacy of a new drug form of diltiazem with delayed release].
    Belousov IuB; Upnitskiĭ AA; Sokolov AV; Tishchenkova NF; Karasev AV; Egorova NA
    Ter Arkh; 1997; 69(3):61-3. PubMed ID: 9229836
    [No Abstract]   [Full Text] [Related]  

  • 30. The antianginal properties of a new porphyrin complex.
    LESLIE RE
    Angiology; 1963 Apr; 14():182-7. PubMed ID: 13929886
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis.
    Khan AR; Farid TA; Pathan A; Tripathi A; Ghafghazi S; Wysoczynski M; Bolli R
    Circ Res; 2016 Mar; 118(6):984-93. PubMed ID: 26838794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug therapy in angina pectoris].
    Follath F
    Praxis (Bern 1994); 1995 Oct; 84(42):1186-9. PubMed ID: 7481332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [How efficacy of antianginal drugs should be evaluated].
    Kośmicki M; Kowalik I; Sadowski Z
    Przegl Lek; 2000; 57(7-8):411-4. PubMed ID: 11109316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of tiphen-promedol in stenocardia and some other diseases].
    SOKOLOV IV
    Sov Med; 1955 Aug; 19(8):26-8. PubMed ID: 13256109
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antianginal agents].
    Smirnov AN
    Feldsher Akush; 1990 Jun; 55(6):51-3. PubMed ID: 2209857
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanical Therapies for Refractory Angina: The Current Evidence.
    Ambesh P; Kapoor A; Obiagwu C; Patel J; Shetty V; Hollander G; Shani J; Kamholz S
    Am J Ther; 2018; 25(3):e369-e374. PubMed ID: 29543611
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effect of hyperbaric oxygenation on the incidence of the antianginal agent withdrawal syndrome in patients with angina pectoris].
    Seriakov VV; Bokarev NV; Burchakova GI; Sidorenko BA; Efuni SN
    Kardiologiia; 1991 Oct; 31(10):32-3. PubMed ID: 1753577
    [No Abstract]   [Full Text] [Related]  

  • 38. Angina pectoris: current therapy and future treatment options.
    Parikh R; Kadowitz PJ
    Expert Rev Cardiovasc Ther; 2014 Feb; 12(2):175-86. PubMed ID: 24417454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antianginal efficacy and tolerability of ivabradine in the therapy of patients with stable angina: results of the CONTROL study].
    Glezer MG; Saĭgitov RT
    Kardiologiia; 2010; 50(11):65-75. PubMed ID: 21526568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The prognosis of the antianginal effect of foridon compared to other antianginal preparations].
    Shkarin VV; Naumova NA; Naumov VG
    Kardiologiia; 1993; 33(3):48-51. PubMed ID: 8377339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.